From Kevin's Desk

Dear Caliper community,

Over the years, we’ve taken great strides toward the realization of the I-I-H Bridge – our concept to build a continuum of experimentation solutions that help scientists effectively bridge in vitro and in vivo experimentation, improving the ability to efficiently and effectively predict human outcome.  

Perhaps the most widely-publicized challenge facing the life sciences industry is enhancement of the productivity of drug discovery.  Although high throughput screening has greatly increased experimental efficiency, it has resulted in dramatically higher failure rates.  Late stage clinical failures have become extraordinarily costly for pharmaceutical companies and truly devastating for smaller biotechnology firms. 

As a leading life sciences platform company, Caliper develops and commercializes  innovative technologies that together improve the predictive nature of preclinical experimentation, increasing quality and accelerating results across the spectrum of life science research.   In fact, Caliper’s technologies, products and services have been recognized by leading pharmaceutical and biotechnology companies as having been pivotal in the discovery of numerous important new drug therapies.

With headquarters in greater Boston, Caliper has sales, service and support operations worldwide, targeted revenues of nearly $140 million, and a strong commitment to life science success evident in a corporate history exceeding 25 years.  Our competitive strength has been to collaborate closely with thought leaders throughout BioPharma and academia to identify leading edge, next generation technologies and to acquire those technologies/companies and transform them into profitable, growing businesses.  But our most significant asset is our team of over 500 qualified, dedicated and innovative employees each of whom are motivated daily by our opportunity to impact the quality of human life.  Many of these employees have come to Caliper from leading pharmaceutical, biotechnology and academic institutions as well as other leading life science technology providers.  We are very proud of this team as well as the caliber of our relationships with thought leaders throughout the industry. 

We hope you enjoy this new website, which is now your integrated source for everything  related to Caliper Life Sciences.       

As always, please let us know if you have any questions and/or ideas on how we can better support you in your quest to develop new drugs and/or improve your overall experimentation strategies.

Best regards,

Kevin


Kevin Hrusovsky
President & CEO
Caliper Life Sciences